Citius merges oncology subsidiary with TenX Keane

By Yahoo! Finance | Aug 13, 2024 at 07:35 AM EST

Citius Pharmaceuticals merged its oncology subsidiary with TenX Keane Acquisition to form Citius Oncology, set to go public on Nasdaq as CTOR. The new company will focus on developing targeted oncology therapies, starting with LYMPHIR, approved by the FDA for CTCL treatment.

Did you find this insightful?

Bad

Just Okay

Amazing

We are preparing, please wait

New Alert

Select an alert type

Sentiment Spike

Send email alert if news sentiment changes significantly

Mentions Spike

Send email alert if has a surge in mentions

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.